APO-RIVASTIGMINE rivastigmine (as hydrogen tartrate) 6mg capsule blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

rivastigmine hydrogen tartrate, Quantity: 9.6 mg

Disponible depuis:

Arrotex Pharmaceuticals Pty Ltd

DCI (Dénomination commune internationale):

rivastigmine hydrogen tartrate

forme pharmaceutique:

Capsule

Composition:

Excipient Ingredients: maize starch; microcrystalline cellulose; Gelatin; iron oxide red; stearic acid; titanium dioxide; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Mode d'administration:

Oral

Unités en paquet:

112, 28, 56, 14

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the Alzheimer's type

Descriptif du produit:

Visual Identification: Hard gelatine calsule with orange, opaque body and red opaque cap. Imprinted "APO R6" in black ink, white to off white fill.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Registered

Date de l'autorisation:

2010-07-27